Retinal Vein Occlusion (RVO) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Retinal vein occlusions (RVO) constitute a heterogeneous group of disorders characterized by impaired venous return from the retinal circulation. Classification of RVO can be subdivided into branch retinal vein occlusion (BRVO), hemiretinal vein occlusion (HRVO), and central retinal vein occlusion (CRVO), depending on the obstruction site. An occlusion within or posterior to the optic nerve head is termed CRVO, an occlusion at the major bifurcation is classified as HRVO, and any obstruction within a tributary is identified as BRVO. HRVO is often considered a distinct condition, exhibiting characteristics intermediate between BRVO and CRVO. Typical atherosclerosis risk factors are commonly associated with all types of RVO, though vein occlusions can also arise secondary to other processes such as inflammation, vasospasm, or compression. Major risk factors for BRVO include systemic arterial hypertension, arteriosclerosis, and diabetes, with additional associations reported, including thrombophilia. Patients with RVO are at risk of vision loss due to several complications from interrupted blood flow, including macular edema, macular ischemia, optic neuropathy, vitreous hemorrhage, and tractional retinal detachment. However, symptoms of RVO can be subtle or absent, particularly in cases of mild severity or when the affected area does not involve the macula. Visual field abnormalities are variably present but are uncommonly symptomatic. Diagnosing retinal vein occlusions is clinical, necessitating thorough examinations to evaluate indications for potential treatment. Routine examination includes assessment of intraocular pressure, slit-lamp examination with undilated gonioscopy, and dilated funduscopy to detect glaucoma, ocular neovascularization, and macular edema. Central venous pressure can be predictive of disease severity. Management of retinal vein occlusion primarily focuses on addressing the disorder’s consequences rather than re-establishing normal venous circulation. Faricimab is the first and only bispecific antibody approved by the FDA for the treatment of the eye. The FDA has also approved farcical (Vabysmo; Genentech) for the treatment of macular edema following retinal vein occlusion (RVO).

Thelansis’s “Retinal Vein Occlusion (RVO) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Retinal Vein Occlusion (RVO) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Retinal Vein Occlusion (RVO) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Retinal Vein Occlusion (RVO) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Retinal Vein Occlusion (RVO) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033